<DOC>
	<DOCNO>NCT01610492</DOCNO>
	<brief_summary>This phase II , open label , experimental medicine study evaluate efficacy , safety mechanism action belimumab subject antiphospholipase A2 receptor ( PLA2R ) autoantibody positive idiopathic membranous glomerulonephropathy ( IMGN ) , profile relationship biomarkers , autoantibody status clinical response . 10 milligram per kilogram ( mg/kg ) belimumab intravenous ( IV ) administer week 0 , 2 , every 4 week , 24-week treatment period subject anti-PLA2R antibody positive IMGN follow long term treatment period subject reach remission proteinuria , maximum 2 year total treatment . All subject receive background supportive therapy throughout study . The dosing frequency adjust every 2 week subject 's proteinuria assess urinary protein creatinine ratio ( PCR ) great 1000 milligram per millimole ( mg/mmol ) [ great 10 gram ( g ) /24 hour ( h ) ] , compensate loss belimumab urine . Effects mechanistic marker measure level proteinuria , level anti-PLA2R antibody , various measure kidney function . These compare historical data . The pharmacokinetics belimumab measure confirm dose heavily proteinuric subject . Pharmacodynamic ( PD ) marker , biomarkers Quality Life ( QoL ) IMGN subject also investigate . Safety assess adverse event ( AE ) , clinical laboratory evaluation , vital sign .</brief_summary>
	<brief_title>A Study Belimumab Idiopathic Membranous Glomerulonephropathy</brief_title>
	<detailed_description />
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Age &amp; Gender : Male female 18 75 year age inclusive , time signing informed consent . Histological diagnosis : Have clinical diagnosis IMGN , verify biopsy ( either light microscope immunofluorescence , electron microscope ) last 7 year nonactive disease &gt; 3 year ( nonactive define subject immunosuppressant proteinuria &lt; 2g per 24h ) ( biopsy result slide available independent evaluation ) . Autoantibody : Have positive antiPLA2R autoantibody test result screen . Proteinuria : Have clinically active disease ( nephrotic range proteinuria ) least 3 month prior screen improvement ( le 30 % reduction ) , despite supportive therapy ( include maximal tolerated dos ACE inhibitor ARB unless contraindicate , may include statin , diuretic , dietary salt restriction ) . During screen proteinuria must great 400mg/mmol PCR ( great 4.0g per 24h ) measure 24 h urine collection and/or spot urine sample ( early morning possible ) 2 occasion least 7 day apart . Female Subjects : A female subject eligible participate pregnant nursing least one follow condition apply : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) great 40 MilliInternational Units per millilitre ( MlU/mL ) estradiol less 40 picograms per milliliter ( le 147 picomoles per liter ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method protocol wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential agrees use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 16 week last dose NonIdiopathic membranous glomerulonephropathy ( MGN ) condition affect kidney : If diagnosis MGN secondary condition , subject renal impairment condition MGN . Severely reduced deteriorate kidney function : An eGFR screen &lt; 40 millilitre ( mL ) /minute ( min ) /1.73 meter ( ) ^2 ( determined 4 variable version Modification Diet Renal Disease equation ) kidney function stable ( defined &gt; 15 % decrease eGFR 3 month screen , unless due medication change ) . Blood Pressure : Uncontrolled hypertension define blood pressure ( BP ) great 150/90 millimeter mercury ( mm Hg ) ( treatment target great equal 140/80 ) assess either : Blood pressure measure 3 time least 2 clinic visit screen , patient sit quietly least 5 minute , great 50 % measurement great 150/90 average daytime blood pressure 24 hour ambulatory blood pressure monitor . Prior Therapy : Have receive treatment follow therapy time specified prior Day 0 : Therapy Bcell target therapy except rituximab ( e.g. , anti CD20 agent , antiCD22 [ epratuzumab ] , antiCD52 [ alemtuzumab ] , B lymphocyte stimulatorreceptor fusion protein [ BR3 ] , transmembrane activator calcium modulator cyclophylin ligand interactor Fc , belimumab ) , Time period : anytime ; Therapy : Rituximab ( Subjects rituximab treatment 1 2 year prior Day 0 eligible document evidence Bcell repopulation &gt; 50 % pretreatment level . ) , Period : 2 year ; Therapy : Abatacept biologic investigational agent B cell target therapy ( i.e . approve sale country use ) , Time Period : 364 day ; Therapy : Cyclophosphamide chlorambucil 3 course systemic corticosteroid concomitant condition ( e.g. , asthma , atopic dermatitis ) . ( Topical inhale steroid permit . ) , Time Period : 180 day ; Therapy : Antitumour necrosis factor ( TNF ) antiIL6 therapy ( e.g . adalimumab , etanercept , infliximab , tocilizumab ) . Interleukin1 receptor antagonist ( e.g . anakinra ) . Other immunosuppressive/immunomodulatory agent ( e.g azathioprine , 6mercaptopurine , mycophenolate mofetil ( PO ) / mycophenolate mofetil hydrochloride ( IV ) , mycophenolate sodium ( PO ) , methotrexate , tacrolimus , sirolimus , thalidomide , leflunomide , mizoribine , ciclosporin ) . Intravenous immunoglobulin ( IVIG ) . Plasmapheresis , leukapheresis , Time Period : 90 day ; Therapy : A nonbiologic investigational agent ( i.e . approve sale country use ) . Intravenous corticosteroid , Adrenocorticotropic hormone ( ACTH ) . Adenocorticotropic hormone ( ACTH ) , aliskiren A change dose &gt; 50 % angiotensin pathway antihypertensive ( e.g. , ACE inhibitor , angiotensin receptor blocker ) , Time Period : 60 day ; Therapy : A live vaccine . Greater 30 milligram per day ( mg/day ) corticosteroid , Time Period : 30 day ; Therapy : Greater 10mg/day corticosteroid . A change dose corticosteroid . Note : Changes inhale steroid new topical immunosuppressive agent ( e.g. , eye drop , topical cream ) allow , Time Period : 14 day ; Transplantation : Have history major organ transplant ( e.g. , heart , lung , kidney , liver ) hematopoietic stem cell/marrow transplant . Cancer : Have history malignant neoplasm within last 5 year , except adequately treat cancer skin ( basal squamous cell ) carcinoma situ uterine cervix . Acute chronic infection : Have require management acute chronic infection , follow : Currently suppressive therapy chronic infection ( tuberculosis , pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster atypical mycobacteria ) ; Hospitalisation treatment infection within 60 day prior Day 0 ; Use parenteral ( IV intramuscular ) antibiotic ( antibacterial , antiviral , antifungal , antiparasitic agent ) within 60 day prior Day 0 . Liver disease : Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Other diseases/conditions : Have clinical evidence significant unstable uncontrolled acute chronic disease due IMGN ( i.e. , cardiovascular , pulmonary , haematologic , gastrointestinal , hepatic , renal , neurological , malignancy infectious disease ) , opinion investigator , could confound result study put subject undue risk . Have plan surgical procedure history medical disease ( e.g . cardiopulmonary ) , laboratory abnormality , condition ( e.g . poor venous access ) , opinion investigator , make subject unsuitable study . Positive serology : Have historically positive human immunodeficiency virus ( HIV ) test test positive screening HIV . Serologic evidence Hepatitis B ( HB ) infection base result test hepatitis B surface ( antigen ) ( HBsAg ) , antiHBc antiHBs follow : Patients positive HBsAg exclude : Patients negative HBsAg antiHBc antibody positive antiHBs antibody history Hepatitis B vaccination exclude ; Patients negative HBsAg positive antiHBc antiHBs antibody exclude ; Patients negative HBsAg antiHBs antibody positive antiHBc antibody exclude . Positive test Hepatitis C antibody confirm sample Hepatitis C Recombinant Immunoblot Assay ( RIBA ) immunoblot assay available . Subjects positive Hepatitis C antibody positive indeterminate result Hepatitis C RIBA immunoblot assay perform sample , Hepatitis C RIBA assay available , eligible participate . Liver function test : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great equal 2x upper limit normal ( ULN ) ; alkaline phosphatase bilirubin great 1.5xULN ( isolate bilirubin great 1.5ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Immunodeficiency : Have IgA deficiency [ immunoglobulin ( Ig ) A level &lt; 10 milligram per deciliter ( mg/dL ) ] IgG level &lt; 250 mg/dL previously receive nonglucocorticoid immunosuppression previous 6 month . Laboratory test abnormality : Have clinically significant abnormality screen laboratory assessment ( related disease ) , judge investigator . Drug sensitivity / Anaphylaxis : History sensitivity intolerance study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History anaphylactic reaction parenteral administration contrast agent , human murine proteins monoclonal antibody . Substance abuse : Evidence current drug alcohol abuse dependence . Blood donation : Where participation study would result donation blood blood product excess 500 mL within 56 day period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>IMGN</keyword>
	<keyword>anti-PLA2R antibody</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>belimumab</keyword>
	<keyword>Benlysta</keyword>
	<keyword>Idiopathic Membranous Glomerulonephropathy</keyword>
	<keyword>safety</keyword>
	<keyword>GSK1550188</keyword>
	<keyword>Lymphostat-B</keyword>
	<keyword>membrane attack complex</keyword>
</DOC>